Robert Postlethwaite
Nessuna posizione attualmente
Storia della carriera di Robert Postlethwaite
Precedenti posizioni note di Robert Postlethwaite
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
AgeneBio, Inc.
 AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Direttore/Membro del Consiglio | 13/05/2010 | - |
Cardinal Equity Partners LLC
 Cardinal Equity Partners LLC Investment ManagersFinance Cardinal Equity Partners LLC (Cardinal Equity Partners) is a private equity firm founded in 1993 by John F. Ackerman, James L. Smeltzer and Peter J. Munson. The firm is headquartered in Indianapolis, Indiana. | Investitore di Private Equity | 26/11/2009 | - |
| Corporate Officer/Principal | 01/01/2008 | 26/11/2009 |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
Posizioni
| Private Equity Investor | 1 |
| Corporate Officer/Principal | 1 |
| Director/Board Member | 1 |
Settori
| Finance | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Cardinal Equity Partners LLC
Cardinal Equity Partners LLC Investment ManagersFinance Cardinal Equity Partners LLC (Cardinal Equity Partners) is a private equity firm founded in 1993 by John F. Ackerman, James L. Smeltzer and Peter J. Munson. The firm is headquartered in Indianapolis, Indiana. | Finance |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Health Technology |
- Borsa valori
- Insiders
- Robert Postlethwaite
- Esperienza
